Cerebrotendinous Xanthomatosis Market Forecasts, 2027 - USA, Canada, France, Germany, Italy, Spain, UK, Japan, Russia, Brazil, Poland, Austria, Netherlands, Turkey, India, China, Mexico, Argentina

Dublin, Jan. 15, 2018 (GLOBE NEWSWIRE) -- The "Cerebrotendinous Xanthomatosis Forecast in 18 Major Markets 2017-2027" report has been added to ResearchAndMarkets.com's offering.

This report provides the current prevalent population for CTX across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, Russia, Brazil, Poland, Austria, The Netherlands, Turkey, India, China, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease caused by mutations in the CYP27A1 gene encoding a cytochrome P450 oxidase, also known as sterol 27-hydroxylase. The lack of the functional enzyme results in a reduced production of chenodeoxycholic acid (CDCA) and cholic acid (CA), components of bile, as well as accumulation of cholestanol and cholesterol in different tissues, e.g., brain, tendons, lenses, bones and vessels. No genotype-phenotype correlations have been identified, and the phenotypic manifestation can vary even between identical twins.

Providing a value-added level of insight, several of the main symptoms and co-morbidities of CTX have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for CTX include:

• Chronic diarrhoea
• Developmental cataracts
• Tendon xanthomas
• Seizures
• Intellectual impairment
• Osteoporosis
  

Reasons to Buy:

• Able to quantify patient populations in global CTX market to target the development of future products, pricing strategies and launch plans
• Gain further insight into the prevalence of the subdivided types of CTX and identify patient segments with high potential
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
• Provide a level of understanding on the impact from specific co-morbid conditions on CTX prevalent population
• Identify sub-populations within CTX which require treatment
• Gain an understanding of the specific markets that have the largest number of CTX patients

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Comorbid Conditions / Features Associated With the Disease
8. Methodology for Quantification of Patient Numbers
9. Top-Line Prevalence for Cerebrotendinous Xanthomatosis
10. Comorbid Conditions of Cerebrotendinous Xanthomatosis Patients
11. Abbreviations Used in the Report
12. Other Publications
13. Online Patient-Based Databases
14. Patient-Based Offering
15. Online Pricing Data & Platforms
16. References
17. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/chwkrd/cerebrotendinous?w=12

                    
                    
                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Endocrine and Metabolic Disorders Drugs